Human Pattern Works published a research paper detailing how a generative AI platform called Pharma.AI was used to find a breakthrough drug candidate Rentosertib for Idiopathic Pulmonary Fibrosis in 18 months.
Public source
Publisher name
Public post
THE BRIGHT SIDE OF AI: REAL-WORLD PHYSICAL/OPERATIONAL BREAKTHROUGHS EPISODE 3: FINDING A BREAKTHROUGH DRUG IN 18 MONTHS INSTEAD OF 10 YEARS It traditionally takes over…
Company
Human Pattern Works
Neuro-inclusive & Human-Centered ¦ Studio for neuro-inclusive, human-centered & sustainable (AI) Transformation.
- Industry
- Business Consulting and Services
- Location
- Horgen, CH
- Company size
- 1 employee
About Human Pattern Works
Human Pattern Works is a Consulting Studio for responsible AI transformation that centers the human experience and neuro-diversity in the Age of AI (Agents). Receive relevant Updates, Freebies and Event Invitations via Mail for Human Pattern Works by Christina Fischer. Subscribe to newsletter at https://lnkd.in/e5hzpNdC I help create Clarity from Confusion: I implement repeatable, scalable patterns for navigating volatile, uncertain, complex and ambiguous patterns for individuals, teams, executives and small to mid-sized organizations. Christina x Design Thinking x Neurodivergent Best Practices x Innovation Engineering = 🧡 @ https://www.humanpattern.works/
See moreLatest activity
Latest activity from Human Pattern Works
3 signals
Presence & Recognition
Human Pattern Works featured the Ig Nobel Prize winner team led by researchers from the University of Zurich taking home the Ig Nobel Soil Science Prize for their experiment with cotton underwear.
Research & Knowledge
Human Pattern Works highlights that Bosch used generative AI to synthesize photorealistic defect images for high-precision manufacturing.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
HealthSeed AG
HealthSeed AG published the first blinded prospective antibody benchmark for AI drug discovery, featuring 511 submissions from 29 organisations across three tasks published in Nature Biotechnology on 19 August, with 71.5 percent of valid submissions bound the target and a winning design reaching 94.7 picomolar in under a week against a laboratory control of 113 picomolar.
Research & Knowledge
Ad Hoc LLC
Ad Hoc LLC reported that a drug designed by AI, rentosertib, moved into Phase III trials and outperformed the standard of care doctors for idiopathic pulmonary fibrosis.
Research & Knowledge
EIGHT ADVISORY
EIGHT ADVISORY reported that 2024-2025 saw $85B poured into AI drug discovery globally, with 75+ AI-discovered molecules now in human trials, 24 in Phase 2, 3 in Phase 3, and no FDA approval yet.
Research & Knowledge
Indegene
Indegene published a case study exploring how a leading biotech company leveraged GenAI to make critical regulatory intelligence more accessible and actionable across the organization.
Research & Knowledge
ProPharma